Biomark Diagnostics Inc
20B
Company Profile
Business description
Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early cancer treatment. Its research and development are focused on the role that metabolomics plays in early cancer detection. The company’s objective is to commercialize its inventive technology. and strive to increase the predictive accuracy in early-stage cancer detection.
Contact
130 - 3851 Shell Road
RichmondBCV6X 2W2
CANT: +1 604 836-6950
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 March 2027
Employees
Stocks News & Analysis
stocks
Margins have bottomed for ASX listed consumer goods company
Impact of tariffs have been priced in.
stocks
SpaceX rally continues, expanding sky-high valuations
SpaceX has risen 50% from its IPO price to become the second-most-expensive stock under Morningstar’s coverage.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,068.10 | 46.30 | 0.51% |
| CAC 40 | 8,421.14 | 46.84 | -0.55% |
| DAX 40 | 24,985.82 | 40.98 | -0.16% |
| Dow JONES (US) | 51,564.70 | 72.15 | 0.14% |
| FTSE 100 | 10,363.27 | 36.43 | -0.35% |
| HKSE | 23,450.46 | 474.35 | -1.98% |
| NASDAQ | 26,517.93 | 496.28 | 1.91% |
| Nikkei 225 | 72,533.14 | 1,283.08 | 1.80% |
| NZX 50 Index | 13,519.22 | 23.59 | 0.17% |
| S&P 500 | 7,500.58 | 80.48 | 1.08% |
| S&P/ASX 200 | 8,850.30 | 48.40 | 0.55% |
| SSE Composite Index | 4,093.78 | 3.30 | 0.08% |